Advanced Translational Research on Childhood Leukemia

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeUp to 18
SponsorChinese University of Hong Kong

About this trial

Prognosis of children with leukemia, the most common pediatric cancer, has improved markedly. Yet, relapse still occurs in 15-40% of patients with a probability of survival of \<50%, which is unlikely to be boosted by intensification of standard chemotherapy due to overwhelming toxicity. The advent of effective and safe targeted therapies for high-risk cases is therefore imperative. This study constitutes two research projects aiming at driving therapeutic advances.

Eligibility criteria

Qualifiers

acute lymphoblastic leukemia (ALL) or

acute myeloid leukemia (AML) or

Disqualifiers

This study will not recruit subjects who are unable to understand English or Chinese.

Patient or parent refusal

Trial design

Treatments tested in this trial

  • RNA-seq
  • whole exon sequencing
  • Cytogenetics test

Treatment groups

300 Participants
are divided into 1 treatment group